The Zhitong Finance App learned that on Thursday, Zaiding Pharmaceutical (ZLAB.US) surged more than 12% to $20.68. According to the news, Zaiding Pharmaceutical announced financial results for the second quarter of 2026. According to financial reports, total revenue for the second quarter of 2026 was US$106.3 million, and net product revenue was US$105.8 million, up 11% month-on-month, thanks to Zelle's steady performance and continued growth in sales of Agamod.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.